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Abstract Since the 1990s, hybrid imaging by means of
software and hardware image fusion alike allows the
intrinsic combination of functional and anatomical image
information. This review summarises in three parts the
state-of-the-art of dual-technique imaging, with a focus on
clinical applications. We will attempt to highlight selected
areas of potential improvement of combined imaging
technologies and new applications. In this first part, we
briefly review the origins of hybrid imaging and comment
on the status and future development of single photon
emission tomography (SPECT)/computed tomography
(CT). In short, we could predict that, within 10 years, we
may see all existing dual-technique imaging systems, includ-
ingSPECT/CT,inclinicalroutineuseworldwide.SPECT/CT,
in particular, may evolve into a whole-body imaging
technique with supplementary use in dosimetry applications.
Keywords Hybrid imaging.SPECT.CT.SPECT/CT.
PET/CT.PET/MR
Introduction
For centuries, medical imaging has been invasive and
potentially harmful to the body of the patient (Fig. 1).
Frequently, diseases were missed or diagnosed too late
because external anatomical changes were observed long
after the onset of disease. During the past century,
technologies have progressed rapidly and have had an
impact on medicine to an extent unseen before. One of the
most cited observations that led to the development of an
entirely new medical discipline was the discovery of X-rays
by Wilhelm Conrad Roentgen in 1895 [1]. The first
applications of X-rays were not necessarily medical, let
alone clinical, and it took a few years before the full scope of
X-ray imaging was explored for the benefit of the patient.
The early 1970s saw the introduction of the first X-ray
computed tomography (CT) system, initially for brain
imaging and then later for whole-body studies [1].
Following CT, the 1980s witnessed the appearance of
clinical magnetic resonance (MR), a technique of particular
importance for imaging patients because it does not require
the use of ionising radiation. These two techniques, CT and
MR, located within radiology departments, came to
dominate the imaging of human anatomy. However, in
diagnosing and staging disease or monitoring response to
therapy, anatomical imaging does not always provide the
complete picture. Functional or metabolic changes may
“The world is greater than the sum of its parts” (Aristotle 384–322
BC).
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Nuclear medicine techniques, initiated in the late 1940s,
image functional processes by using radioactive tracers and
photon detectors. Tomographic imaging with radionuclides
actually predates CT, with early attempts dating from 1963
[2]. The first human tomographic images with positron-
emitting isotopes were presented in 1972 [3], thus establish-
ing positron emission tomography (PET) on the map of
medical imaging technologies, to be joined by single photon
emission tomography (SPECT) a year or so later, following
on from the pioneering work of the early 1960s [4].
Various methods of imaging have become available over
the past century that have made patient observation, disease
diagnosis and therapy follow-up feasible, and above all non-
invasive. We know that disease originates from physical
distress as well as from changes on the molecular and
physiological level. In most cases of serious diseases, early
diagnosis is key and, therefore, imaging the anatomy of a
patient may not suffice in making a correct and timely
diagnosis. Therefore, medical doctors typically employ a
combination of imaging techniques during the course of
diagnosis and subsequent treatment to monitor their patients.
In other words, both functional and anatomical information
are essential in state-of-the-art patient management. An
appreciation for this type of combined information is best
illustrated with the introduction of the term “anato-metabolic
imaging” [5], in reference to an imaging technique that
gathers both anatomical and functional information, ideally
within the same examination.
The advantages of integrated, anato-metabolic imaging
are manifold [6]. First, a single examination would provide
comprehensive information on the state of a disease. Here,
functional, and thus, less anatomically accurate information
would be gathered and displayed in a widely appreciated
anatomical context. Second, patients would be invited for
only one, instead of two or multiple examinations. Third,
while engineering costs for combined imaging devices may
initially be high, customers would benefit from purchasing
a single device rather than two independent devices.
Fourth, as we will see later on, the combination of
complementary imaging techniques can yield synergy
effects for the acquisition and processing of image data.
Fifth, experts in radiology and nuclear medicine are
hopefully forced to discuss and integrate their knowledge
into one report.
While each of the above points can be debated, it is
generally assumed that combined imaging has revolution-
ised imaging and medical diagnosis. Nonetheless, while
technological innovation always partners enthusiasm and
public interest, subsequent devices and imaging techniques
must be affordable and assessed for their health benefit to
justify their introduction into a public healthcare system [7].
Unfortunately, today, over 10 years after the introduction of
the first commercial dual-technique imaging systems,
technology assessment and cost-benefit analyses are not
applied to the same standards across imaging techniques.
Here, we intend to describe briefly the status of combined
imaging and, based on recent developments, hypothesise on
the short-term future of dual- and multi-technique imaging.
Further, we willhighlight requirements for supporting a wider
dissemination of hybrid imaging.
Hybrid imaging technologies
Historically, medical devices to image either anatomical
structure or functional processes have developed along
Fig. 1 From invasive to
non-invasive imaging. It took
more than 500 years to establish
non-invasive imaging from the
pencil drawings of Da Vinci to
routine tomographic imaging.
Fifty years were needed to
introduce hybrid imaging. With
the availability of stand-alone
anatomical and functional
imaging, the first attempts to
fuse separately acquired images
were made as early as the 1960s.
Computer-assisted software
fusion can be regarded as a main
incubator of hardware fusion,
first introduced in the late
1980s, a decade before proto-
type hardware-fusion
became available
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ing images from different techniques can nevertheless offer
significant diagnostic advantages gave rise to sophisticated
software techniques to co-register structure and function
retrospectively [8, 9]. The usefulness of combining ana-
tomical and functional planar images was evident to
physicians as early as the 1960s [2]. In addition to simple
visual alignment, or the use of stereotactic frames that are
undesirable or inconvenient for diagnostic imaging, sophis-
ticated image fusion software was developed from the late
1980s onwards. For relatively rigid objects such as the
brain, software can successfully align images from MR, CT
and PET, whereas in more flexible environments, such as
the rest of the body, accurate alignment is difficult owing to
the large number of possible degrees of freedom.
Alternatives to software-based fusion have now become
available through instrumentation that combines two
complementary imaging techniques within a single gantry,
an approach that has since been termed “hardware fusion”
(Fig. 2). A combined, or hybrid, tomograph such as
SPECT/CT or PET/CT can acquire co-registered structural
and functional information within a single study. The data
are complementary allowing CT to accurately localise
functional abnormalities and SPECT or PET to highlight
areas of abnormal metabolism.
As a result, following their introduction into the clinic,
combined PET/CT and SPECT/CT devices are now playing
an increasingly important role in the diagnosis and staging
of human disease. Recently, the first clinical PET/MR
prototype systems have started to undergo clinical evalua-
tion and, furthermore, other imaging combinations are
being discussed.
SPECT/CT
Background and reasoning
In 1996, Blankespoor and co-workers presented a com-
bined SPECT/CT design comprising a clinical SPECT
gamma camera in tandem with a clinical single-slice CT
[10]. The images were co-registered by taking into account
the axial displacement between the CT and SPECT imaging
fields. After injection of the radiotracer and an uptake
period, the patient was imaged first with CT and subse-
quently with SPECT. The CT data were used to generate
the SPECT attenuation correction factors [11]. The com-
bined device was used to perform a small number of
clinical studies, such as for quantitative estimation of
radiation dosimetry in brain tumour patients [12].
Since then, SPECT/CT has advanced rapidly and several
commercial system designs are available today (Fig. 3).
The Infinia Hawkeye series (GE Healthcare) has remained a
viable option for SPECT imaging combined with low
resolution anatomy [13, 14]. The latest design, the Infinia
Hawkeye 4, features a four-row detector unit with a rotation
speed of 23 s. An axial field of 40 is now acquired in about
3–4 min. Apart from their obvious role in localisation, the
anatomical images can be used to generate attenuation
correction factors. This is more advantageous for SPECT
Fig. 2 Attempts to combine anatomical and functional image information in clinical routine from 1960 to 2000
Insights Imaging (2011) 2:161–169 163than for PET because the SPECT attenuation correction
factors depend on the (unknown) depths in tissue of the
detected photons (Fig. 4).
In 2004 the first combined clinical SPECT/CT system,
the Symbia T2 (Siemens Medical Solutions), was
launched comprising a dual-slice Emotion CT and a
dual-head Symbia S scintillation camera. This is the first
commercial design that incorporated a fully-clinical CT
system. This design, now named the Symbia TruePoint
SPECT/CT, is also available with 6-slice and 16-slice
Emotion CT systems. Philips Healthcare now offers a
high-performance SPECT/CT with their Precedence plat-
form. The design is available with a 16-slice CT that has
a minimum rotation time of 0.4 s. Similarly, GE Health-
care added a SPECT/CT to their product portfolio. The
NM/CT 670 combines a SPECT system with a 16-slice
BrightSpeed Elite with 0.5 s rotation time. Finally,
Hungary-based Mediso company offers a SPECT system
that can be combined with CT (and even PET). The CT
is a 16-slice spiral system. A trend seen from Fig. 3 is
the combination of state-of-the-art SPECT detector heads
with mid-tier clinical CT, a combination that was previ-
ously described as potentially more useful than combining
CT and PET [15].
Main applications
The Hawkeye has experienced increasing popularity for
SPECT where even low-resolution anatomy can have a
significant impact on image interpretation. Numerous
studies performed on Hawkeye systems have confirmed
the utility of co-registered anatomical information for the
interpretation of SPECT images [13, 16].
The introduction of SPECT/CT in 2004 offers physicians
the additional choice of a fully clinical CT study aligned
with the SPECT study. SPECT imaging has access to a
much wider range of clinically established biomarkers and
radiopharmaceuticals than clinical PET, which, today, is
limited mainly to [
18F]FDG (FDG) for glucose utilisation
and
82Rb for cardiac perfusion studies. The fusion of CT
and SPECT images from stand-alone systems has already
demonstrated clinical utility [17]. Thus, hardware fusion of
SPECT with a 16-slice CT offers interesting further
Fig. 3 Selected state-of-the-art
SPECT/CT systems. Since the
introduction of the first com-
mercial SPECT/CT system
employing a dual-head SPECT
and a low-dose, single-slice
CT-like transmission source in
1999, SPECT/CT has advanced
towards a hardware combination
of multiple SPECT detector
heads and spiral CT systems
Fig. 4 With the introduction of
SPECT/CT, attenuation correc-
tion has been made routinely
available to SPECT, and, there-
fore, helped to improve image
and diagnostic quality of the
SPECT for a variety of applica-
tions: (a) brain, (b) cardiac and
(c) skeletal imaging. (Adapted
from Buck et al. [16])
164 Insights Imaging (2011) 2:161–169possibilities for cardiac SPECT. The combination of
calcium scoring from CT and a cardiac SPECT study with
201Tl for tissue viability and
99mTc-sestamibi for perfusion
is an attractive possibility.
Some of the SPECT tracers are highly specific to the
disease process and the corresponding images offer little
o rn oa n a t o m i c a li n f o r m a t i o nc o m p a r e dw i t ha nF D G
whole-body study. Examples of such specific biomarkers
include
123Ia n d
131I for metastatic thyroid disease and
131I-labelled cholesterol for adrenal studies. SPECT/CT
c a na l s op l a ya ni m p o r t a n trole in imaging benign and
malignant bone disease most commonly with
99mTc-
methylene diphosphonate (
99mTc-MDP) to distinguish foci
of increased metabolism [18], and neuro-endocrine tumour
imaging with
111In-octreotide,
111In-pentetreotide or
123I-
MIBG where uptake can be highly tumour-specific and
impossible to localise anatomically without the co-
registered CT [16, 19]. In bone imaging, for example,
combined SPECT/CT may improve diagnostic accuracy
compared with SPECT only [20, 21] and help distinguish
between osteomyelitis, aseptic necrosis and metastatic
disease. As with PET/CT, SPECT/CT has been shown to
be beneficial in recurrent head and neck cancer imaged
with
123I-IMT {L-3[
123I]-iodo-alpha-methyl tyrosine
(IMT)-SPECT}. The accuracy of sentinel node mapping
is improved by accurately localising the affected nodes
(Fig. 5). The co-registered CT should also improve the
diagnostic accuracy of
111In-capromab pendetide (Pros-
taScint) imaging for prostate cancer, a disease for which
FDG-PET is of questionable value although other PET
biomarkers not yet clinically available show some prom-
ise. Finally, myocardial perfusion scintigraphy by SPECT
is one of the most widely used and well established non-
invasive tools for the diagnosis of ischaemic heart disease
with a documented high diagnostic accuracy [22]. The first
promising results with
82Rb-PET perfusion imaging [23]
notwithstanding, combined SPECT/CT imaging can pro-
vide such unique complementary information on coronary
anatomy as well as on pathophysiological lesion severity,
which improves diagnostic assessment and risk stratifica-
tion and helps make decisions with respect to revascular-
isation in patients with coronary artery disease.
Furthermore, SPECT/CT helps to overcome heteroge-
neous photon attenuation in the thorax—one of the most
notable limitations of myocardial perfusion scintigraphy.
T h ei n t e g r a t i o no fC Td a t af o rattenuation correction
(Fig. 4) supports clinically relevant improvements in
diagnostic testing [24, 25].
Fig. 5a–e SPECT/CT case acquired on Symbia T2 (Siemens Health-
care). A 54-year-old woman with breast carcinoma (pT1) for SLN
mapping. Planar scintigraphy (a) detected sentinel lymph node (SLN).
Subsequent SPECT/CT shows two SLNs: one in (b) typical local-
isation and (c, d) one in the upper axilla with 7-mm diameter.
Histology proved the second SLN to be malignant (e). Imaging
protocol: 102 MBq
99mTc-nanocolloid, 0 min pi scintigraphy, 75 min
pi SPECT/CT; CT: 100 mAs, 130 kVp, 1-mm/3-mm slices; SPECT:
15 s/image, FBP, no CT-AC. (Courtesy of L.S. Freudenberg,
Grevenbroich, Germany)
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performed with Hawkeye systems and, therefore, the
addition of clinical CT to SPECT can only enhance the
results obtained to date. As the installed base of SPECT/CT
systems grows, publications documenting the benefits will
no doubt appear in the literature [21, 26].
Improvements and new applications
With routine availability of CT-based attenuation correction
SPECT/CThasbeenwidelyadoptedinfavourofSPECT-only
imaging. However, unlike PET/CT which has replaced most
standalone PET-only systems, SPECT/CT is unlikely to
replace all, or even most SPECT. When compared to PET/
CT most technical and methodological advances of SPECT,
however,arenotonlyavailabletoSPECT/CTusersbutalsoto
SPECT-only users.
Recently, a number of innovative hardware combinations
of SPECT and CT were proposed, giving rise to the idea of
disease-specific SPECT/CT imaging. Gambhir et al. [27]
and Buechel et al. [28] demonstrated the clinical feasibility
and technological benefit of a CdZnTe (CZT)-based SPECT
imaging for cardiac applications. While this system is not
combined with CT, it illustrates a major leap in SPECT
instrumentation that could potentially enter into a new
combination of SPECT/CT. The main benefit of CZT over
standard scintillator-based SPECT detectors is the much
higher energy resolution, which can be explored for dual-
isotope imaging. CZT detectors are compact and future
CZT SPECT/CT could be more physically integrated.
However, today, production costs still limit the wider
distribution of these novel SPECT imaging systems.
Already with standard SPECT in combination with CT
several groups have demonstrated an increased diagnostic
benefit from the availability of co-registered functional and
anatomical information in combination with dedicated CT
examinations, like angiography [17, 29]. So far these
studies have been based on the retrospective alignment of
SPECTand CTangiography data acquired on a 64-slice CT.
Today, no SPECT/CT system would allow similar type of
imaging sequences because of the limited number of CT
detector rows (maximum 16, Fig. 3). It is fair to assume
that if more SPECT-CT software fusion studies demonstrate
the validity of hardware-based acquisitions of SPECT and
CTA, then such combinations may well be designed and
offered commercially.
In addition to cardiac applications, SPECT/CT can be
optimised for orthopaedic imaging. Here, requirements
entail fast and sensitive SPECT imaging in combination
with high-resolution anatomical background information.
As the age distribution of orthopaedic patients is very large,
overexposure is a major concern when imaging these
patients. Therefore, one vendor has proposed a novel
design of SPECT/CT that combines a standard dual-head
SPECT system with a cone-beam, flat-panel CT (Fig. 6)
[30]. A single, 47-cm axial field-of-view of the SPECT is
matched by three contiguous CT acquisitions of 14-cm
axial field-of-view flat panel CT, thus allowing the co-axial
SPECT/CT imaging range per bed position to be 42 cm.
Other innovations in SPECT/CT are expected from
advanced data processing and acquisition (Fig. 7). As with
nuclear medicine imaging techniques in general, SPECT
describes a count limited imaging situation. Therefore,
innovative image reconstruction techniques have been
proposed to reduce noise propagation during the recon-
Fig. 6 (a)S P E C T / C Td e s i g n
with flat panel CT for high-
resolution, low-dose CT imag-
ing with a main focus on ortho-
paedic applications (b) and
routine attenuation correction.
System images courtesy of
Philips Healthcare, case study
courtesy of T. Krause,
Inselspital, Bern, Switzerland
166 Insights Imaging (2011) 2:161–169Fig. 7a–d Examples of method-
ological advances in SPECT/CT
imagingandfutureapplications.a
Advanced three-dimensional
(3D) iterative SPECT
reconstruction (Astonish, Philips
Healthcare) incorporating
projection-based collimator/COR
distance information, collimator
resolution, noise reduction and
attenuation/scatter correction.
(Courtesy of Antonis Kalemis,
Philips Healthcare) b An
example of a segmented CT of
the thorax showing the individual
lobes of the lung. The colours
indicate different regions of
interest, which are applied to the
co-registered lung image to
derive anatomically accurate
functional values for ventilation
and perfusion from the SPECT
lung scan. (Courtesy Dale Bailey,
Royal Northshore Hospital,
Sydney, Australia) c Voxel-based
dosimetry from 3D SPECT(/CT).
SPECT data following CT-AC
are collected for multiple time
points. CT-based organ
segmentation and SPECT-based
lesion segmentation is performed
on SPECT/CT images. Local
dosimetry is possible and isodose
curved and dose-volume
histograms can be calculated.
(Courtesy of Bernd Schweizer,
Philips Healthcare) d
Whole-body SPECT(/CT):
patient with severe back pain
with multiple focal uptakes on
the scintigram. A contiguous
two-bed SPECT/CT acquisition
reveals several bone metastases
in the spine and pelvis.
Multi-bed, or whole-body
SPECT/CT helps with the
complete restaging of the patient,
and is in synchrony with similar
referring indications for
whole-body PET/CT, which is
already widely available.
(Courtesy of Ora Israel, Haifa)
Insights Imaging (2011) 2:161–169 167struction (Fig. 7a). SPECT/CT images, even when based on
low-dose CT acquisitions, provide the ability to anatomi-
cally define the fissures separating the lobes of the lungs so
that lobar function can be assessed semi-automatically from
co-registered V/Q images in patients who are candidates for
lung volume reduction surgery (Fig. 7b). Similar
approaches are followed when employing SPECT/CT
information for image-based dosimetry calculations
(Fig. 7c). Finally, Fig. 7d illustrates the potential of multi-
bed, whole-body SPECT/CT imaging in oncology. Similar
to PET/CT imaging, patients are injected with a single dose
of radioactivity for SPECT/CT imaging. Imaging only a
single bed position makes suboptimal use of the injected
activity. Moreover, in oncology patients, disease can be
widely distributed and not covered appropriately with a
single bed position of SPECT/CT imaging. Here, a case of
a patient with severe back pain with multiple foci of
increased tracer uptake on the planar scintogram is shown.
A two-bed SPECT/CT acquisition reveals several bone
metastases in the spine and pelvis. Multi-bed, or whole-
body SPECT/CT helps with the complete restaging of the
patient, and is in synchrony with similar referring indica-
tions for whole-body PET/CT.
Since the commercial introduction of SPECT/CT in
2004, adoption of the technology has been rapid,
particularly for oncology and cardiology. SPECT/CT
has benefited from the advances in CT technology.
SPECT/CT currently has a smaller installed base than
PET/CT, but it is growing. In 2006, there were about 21-
million SPECT studies performed in the USA compared
with 1.5-million PET and PET/CT studies. The likelihood
is that SPECT/CT will continue to grow with expanding
applications in cardiology, oncology, infectious disease
imaging and others, thereby benefiting from a much
wider range of biomarkers and radiopharmaceuticals than
clinical PET.
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